ArticleRheumatology (Oxford, England)2026
Loss of antiphospholipid antibody positivity decreases the risk of recurrent thrombosis in thrombotic antiphospholipid syndrome.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
objectiveTo establish the predictive value of antiphospholipid antibody (aPL) negativization on recurrent thrombosis in thrombotic antiphospholipid syndrome (APS).
methodsRetrospective cohort study including all consecutive adult patients with APS followed at Hospital de Santa Maria, Lisbon, Portugal, up to December 2024. At diagnosis, all patients were positive for solid-phase aPL. Then, patients were categorized in two groups according to aPL during follow-up: (i) persistently aPL-positive; (ii) aPL-negativization defined as previous aPL-positive and current aPL-negative (two consecutive times, ≥12 months apart). Outcomes included recurrent thrombosis under antithrombotic therapy. Predictors of aPL-negativization and recurrent thrombosis were assessed using Cox regression analysis.
resultsOf the 116 included patients (female, 78.4%; primary APS, 72.1%; triple positivity, 40.5%), totalling 1084 patient years (PY), 31.9% became aPL-negative (3.4 events/100PY). The follow-up time was similar between aPL-positive and aPL-negativization groups (P = 0.681), and before and after aPL-negativization (P = 0.072). At diagnosis, triple aPL-positivity predicted against aPL-negativization, while primary APS predicted aPL-negativization. Forty-five patients (38.8%) experienced 68 recurrences (4.2 events/100PY). Age at APS onset, arterial thrombosis and persistent triple aPL-positivity predicted recurrence. Globally, aPL-negativization did not predict recurrence (HR 0.58, 95%CI 0.29-1.14). Among patients who became aPL-negative, the cumulative incidence of recurrent thrombosis did not differ before aPL-negativization (HR 0.52, 95%CI 0.26-1.06) but dropped by 88% after aPL-negativization (HR 0.12, 95%CI 0.05-0.58), even after adjusting for age, primary APS and type of initial thrombosis (P = 0.006).
conclusionThe risk of recurrent thrombosis drops significantly after aPL-negativization, highlighting the utility of serial aPL monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.